Doximity (DOCS) stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance.
Still, a closer look under the hood suggests these explosive gains are built on a fragile foundation, and the company might just end up paring them back in the days ahead.
In fact, Doximity shares have already reversed a huge chunk of their intraday gains, now up some 33% versus their previous close.
Why Q1 revenue doesn’t warrant buying Doximity stock
In the earnings release, Doximity’s management framed the quarter as a “reacceleration”.
However, total revenue came in up just 7% year-over-year to $156.6 million. For a digital health platform trading at premium software multiples post-rally, single-digit organic revenue growth is relatively weak.
Its core advertising business from pharmaceutical clients remains constrained due to “tightening” healthcare marketing budgets, meaning true acceleration has yet to materialize in reported sales.
Guidance is being treated as more bullish than it actually is
DOCS shares soared primarily on raised FY27 revenue, but the math may not be as bullish as the price action suggests.
The company raised its full-year outlook by $6 million ($671 million to $681 million) – and it beat Q1 revenue estimated by $4.9 million ($156.6 million vs. $151.2 million expected).
What this means is: management passed through the first-quarter outperformance to the full-year target while keeping back-half expectations almost unchanged.
Furthermore, Q2 revenue guidance ($170 million to $171 million) came in essentially in line with the consensus ($171.1 million), offering zero upside surprise for the current quarter.
Margin pressure could hurt DOCS shares
What’s also worth mentioning is that much of the commentary driving Doximity’s stock price rally centered on its AI Search tool.
Yet, the filing actually revealed key friction points as well.
For starters, management said no revenue from the new artificial intelligence tools was recognized in Q1 – with CFO Matthew Sonefeldt adding that “higher-than-expected” AI usage will require expanding AI infrastructure investments in FY2027.
This could prove bearish as computing costs for clinical LLM queries could erode DOCS’s exciting 48% adjusted EBITDA margins as adoption scales.
Why else is Doximity not attractive to own in 2026?
Finally, it’s reasonable to take profit in DOCS stock because the firm’s net revenue retention rate, a key metric measuring how much existing clients expand their spending, sat at 107% on a trailing 12-month basis.
Even among its top 20 largest clients, NRR was 112% – well below the 115% to 120% that premium SaaS and enterprise health platforms typically target.
This means upselling existing pharmaceutical brands and hospital networks remains sluggish.
Put all of it together with Doximity’s adjusted EPS of $0.29 in Q1, which missed the consensus set at $0.30, and the rally immediately starts appearing like an opportunity to trim.
The post Doximity stock is reversing post-earnings rally: why that shouldn’t surprise you appeared first on Invezz
